Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil
Abstract Background Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes. This study evaluated real-world practice among urologists treating patients re...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12894-025-01701-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571220754694144 |
|---|---|
| author | Juan Manuel Palacios Pratiksha Kapse Vanessa Cortes Marcio Augusto Averbeck Alberto Budia Alba Suryakant Somvanshi Danilo Souza Lima da Costa Cruz Fiona Pereira |
| author_facet | Juan Manuel Palacios Pratiksha Kapse Vanessa Cortes Marcio Augusto Averbeck Alberto Budia Alba Suryakant Somvanshi Danilo Souza Lima da Costa Cruz Fiona Pereira |
| author_sort | Juan Manuel Palacios |
| collection | DOAJ |
| description | Abstract Background Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes. This study evaluated real-world practice among urologists treating patients receiving 5-alpha reductase inhibitors. Methods This non-interventional, cross-sectional study collected data from urologists in Spain (N = 100) and Brazil (N = 100) via a self-reporting questionnaire and patient record forms. Endpoints included: frequency/methodology of prostate-specific antigen monitoring, concerns about the effect of 5-alpha reductase inhibitors on prostate-specific antigen monitoring, triggers of prostate biopsy, and concerns when switching 5-alpha reductase inhibitor formulation. Results Over half of urologists monitored prostate-specific antigen every 6 months (Spain 59%, Brazil 58%). Preferred methods were the “doubling rule” (Spain 66%, Brazil 41%) and “increase from nadir” (Spain 28%, Brazil 43%). A minority of urologists monitored unadjusted values (Spain 3%, Brazil 11%) or did not monitor prostate-specific antigen (Spain 1%, Brazil 3%). Most urologists ranked the potential for 5-alpha reductase inhibitors to mask prostate cancer as their top concern (Spain 65%, Brazil 56%). The most selected trigger for prostate biopsy was “if doubled (adjusted) prostate-specific antigen level after 6 months of treatment is > 4 ng/mL” (Spain 39%, Brazil 37%). Many urologists were moderately/very concerned about the effect on prostate-specific antigen when switching 5-alpha reductase inhibitor formulation. Conclusions An unmet need exists for standard guidance and continuous education to support optimal monitoring and interpretation of prostate-specific antigen in patients with lower urinary tract symptoms/benign prostate enlargement treated with 5-alpha reductase inhibitors. |
| format | Article |
| id | doaj-art-260a244a0ff24feabed7baa50304da37 |
| institution | Kabale University |
| issn | 1471-2490 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj-art-260a244a0ff24feabed7baa50304da372025-02-02T12:44:21ZengBMCBMC Urology1471-24902025-01-012511910.1186/s12894-025-01701-1Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and BrazilJuan Manuel Palacios0Pratiksha Kapse1Vanessa Cortes2Marcio Augusto Averbeck3Alberto Budia Alba4Suryakant Somvanshi5Danilo Souza Lima da Costa Cruz6Fiona Pereira7Global Medical Urology, GSKGlobal Medical Urology, GSKGlobal Medical Infectious Diseases, GSKDepartment of Urology, Moinhos de Vento Hospital and Department of Urology, São Lucas Hospital – PUCRSDepartment of Urology, La Fe University and Polytechnic HospitalDev Biostats, India Stats, GSKDepartment of Urology, State University of Rio de JaneiroBrand and Integrated Research Solutions, IQVIAAbstract Background Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes. This study evaluated real-world practice among urologists treating patients receiving 5-alpha reductase inhibitors. Methods This non-interventional, cross-sectional study collected data from urologists in Spain (N = 100) and Brazil (N = 100) via a self-reporting questionnaire and patient record forms. Endpoints included: frequency/methodology of prostate-specific antigen monitoring, concerns about the effect of 5-alpha reductase inhibitors on prostate-specific antigen monitoring, triggers of prostate biopsy, and concerns when switching 5-alpha reductase inhibitor formulation. Results Over half of urologists monitored prostate-specific antigen every 6 months (Spain 59%, Brazil 58%). Preferred methods were the “doubling rule” (Spain 66%, Brazil 41%) and “increase from nadir” (Spain 28%, Brazil 43%). A minority of urologists monitored unadjusted values (Spain 3%, Brazil 11%) or did not monitor prostate-specific antigen (Spain 1%, Brazil 3%). Most urologists ranked the potential for 5-alpha reductase inhibitors to mask prostate cancer as their top concern (Spain 65%, Brazil 56%). The most selected trigger for prostate biopsy was “if doubled (adjusted) prostate-specific antigen level after 6 months of treatment is > 4 ng/mL” (Spain 39%, Brazil 37%). Many urologists were moderately/very concerned about the effect on prostate-specific antigen when switching 5-alpha reductase inhibitor formulation. Conclusions An unmet need exists for standard guidance and continuous education to support optimal monitoring and interpretation of prostate-specific antigen in patients with lower urinary tract symptoms/benign prostate enlargement treated with 5-alpha reductase inhibitors.https://doi.org/10.1186/s12894-025-01701-15-alpha reductase inhibitorsBenign prostatic hyperplasiaBenign prostate enlargementProstate-specific antigenReal-world data |
| spellingShingle | Juan Manuel Palacios Pratiksha Kapse Vanessa Cortes Marcio Augusto Averbeck Alberto Budia Alba Suryakant Somvanshi Danilo Souza Lima da Costa Cruz Fiona Pereira Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil BMC Urology 5-alpha reductase inhibitors Benign prostatic hyperplasia Benign prostate enlargement Prostate-specific antigen Real-world data |
| title | Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil |
| title_full | Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil |
| title_fullStr | Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil |
| title_full_unstemmed | Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil |
| title_short | Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil |
| title_sort | monitoring of prostate specific antigen in men with benign prostate enlargement receiving 5 alpha reductase inhibitors a non interventional cross sectional study of real world practice of urologists in spain and brazil |
| topic | 5-alpha reductase inhibitors Benign prostatic hyperplasia Benign prostate enlargement Prostate-specific antigen Real-world data |
| url | https://doi.org/10.1186/s12894-025-01701-1 |
| work_keys_str_mv | AT juanmanuelpalacios monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT pratikshakapse monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT vanessacortes monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT marcioaugustoaverbeck monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT albertobudiaalba monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT suryakantsomvanshi monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT danilosouzalimadacostacruz monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil AT fionapereira monitoringofprostatespecificantigeninmenwithbenignprostateenlargementreceiving5alphareductaseinhibitorsanoninterventionalcrosssectionalstudyofrealworldpracticeofurologistsinspainandbrazil |